Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 736-744

  Sale, S ^a   Verschoyle, R D ^a   Boocock, D ^a   Jones, D J L ^a   Wilsher, N ^b   Ruparelia, K C ^b   Potter, G A ^b   Farmer, P B ^a   Steward, W P ^a   Gescher, A J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Chemoprevention; Drug design; Metabolism; Resveratrol; Stilbene

Indexed keywords

3,4,5,4' TETRAMETHOXYSTILBENE; 3,4,5,4'-TETRAMETHOXYSTILBENE; ANTINEOPLASTIC AGENT; DMU 212; DRUG METABOLITE; GLUCURONIC ACID; RESVERATROL; STILBENE DERIVATIVE; SULFATE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHROMATOGRAPHY; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG HYDROXYLATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG SCREENING; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; ISOMERISM; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DRUG DESIGN; HYDROXYLATION; ISOMERISM; MICE; STILBENES; TISSUE DISTRIBUTION;

EID: 10744229260     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601568     Document Type: Article

References (45)

1. Asensi M, Medina I, Ortega A, Carrertero J, Bano MC, Obrador E, Estrela JM (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol Med 33: 387-398
2. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002) Suppression of 7,12 dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954
3. Bertelli AAE, Giovannini R, Stradi R, Urien S, Tillement JP, Bertelli A (1996) Kinetics of trans-and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharm Res 16: 77-81
4. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456-7463
5. Chun YJ, Kim MY, Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262: 20-24
6. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 61: 8164-8170
7. De Santi C, Pietrabissa A, Mosca F, Pacifici GM (2000) Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30: 1047-1054
8. Doherty MM, Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41: 235-253
9. Eisenhofer G, Coughtrie MW, Goldstein DS (1999) Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol 26: S41-S53
10. Gehm BD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143
11. Gignac EA, Bourquin LD (2001) Influence of resveratrol and sulindac on intestinal tumor numbers in Min mice. FASEB J 15: A630
12. Goldberg DA, Yan J, Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87
13. Guengerich FP, Chun YJ, Kim D, Gillam EMJ, Shimada T (2003) Cytochrome P4501B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524: 173-182
14. Gusman J, Malonne H, Atassi G (2001) A re-appraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117
15. Haworth RS, Avkiran M (2001) Inhibition of protein kinase D by resveratrol. Biochem Pharmacol 62: 1647-1651
16. Jang MS, Cai EN, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn DA, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220
17. Juan ME, Buenafuente J, Casals I, Planas JM (2002) Plasmatic levels of trans-resveratrol in rats. Food Res Int 35: 195-199
18. Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ (2002) Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P4501B1 inhibitors. J Med Chem 45: 160-164
19. Kuhnle G, Spencer JPE, Chowrimootoo G, Schroeter H, Debnam ES, Srai SKS, Rice Evans C, Hahn U (2000) Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272: 212-217
20. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y, Imamura M (2002) Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratroL Carcinogenesis 23: 1531-1536
21. Lu JB, Ho CT, Ghai G, Chen KY (2001) Resveratrol analog, 3,4,5,4′-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 22: 321-328
22. Mahyar-Roemer M, Katsen A, Mestres P, Roemer K (2001) Resveratrol induces colon tumor cell apoptosis independently of p53 and preceded by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer 94: 615-622
23. Mahyar-Roemer M, Kohler H, Roemer K (2002) Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells. BMC Cancer 2: 27-35
24. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau J-P, Ducharme MP (2002) Metabolism and disposition of resveratol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharm Exp Ther 302: 369-373
25. Mutoh M, Takahashi M, Fukuda K, Matsushima-Hibiya Y, Mutoh H, Sugimura T, Wakabayashi K (2000) Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21: 959-963
26. Nam KA, Kim S, Heo YH, Lee SK (2001) Resveratrol analog 3,5,2′,4′-tetramethoxy-trans-stilbene, potentiates the inhibition of cell growth and induces apoptosis in human cancer cells. Arch Pharmacol Res 24: 441-445
27. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F (1995) Antineoplastic agents 291. Isolation and synthesis of combretastatin A4, A5 and A6. J Med Chem 38: 1666-1672
28. Potter GA, Butler PC, Ruparelia KC, Ijaz T, Wilsher NC, Wanogho E, Tan HL, Hoang TTV, Stanley LA, Burke MD (2002a) DMU212: a novel CYP1B1 activated anticancer prodrug. Br J Cancer 86(Suppl 1): S117
29. Potter GA, Patterson LH, Burke MD, Butler PC (1999) Aromatic hydroxylation activated prodrugs. Int Patent Applic No. WO 99/40056
30. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD (2002b) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778
31. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defense- related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39: 102-107
32. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, Seiler N, Raul F (2000) Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91
33. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A (2001) Resveratrol, a natural phenolc compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res Gen Toxicol Env Mutagen 496: SI171-SI180
34. She QB, Ma WY, Wang MF, Kaji A, Ho CT, Dong ZG (2003) Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene 22: 2143-2150
35. Shimada T, Sugie A, Shindo M, Nakajima T, Azuma E, Hashimoto M, Inoue K (2003) Tissue-specific induction of cytochrome P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. Toxicol Appl Pharmacol 187: 1-10
36. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ (2003) Inhibition of protein kinase C by resveratrol. Biochem Biophys Acta 1637: 59-69
37. Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM (2001) Absorption of trans-resveratrol in rats. Methods Enzymol 335: 145-154
38. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang MS, Pezzuto JM, Dannenberg AJ (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875-21882
39. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat Res 480-481: 243-268
40. Tessitore L, Davit A, Sarotto I, Caderni G (2000) Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21: 1619-1622
41. Uenobe F, Nakamura S, Miyazawa M (1997) Antimutagenic effect of resveratrol against Trp-P-1. Mutat Res 373: 197-200
42. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J, Merillon JM (2003) Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72: 2219-2233
43. Wolter F, Akoglu B, Clausnitzer A, Stein J (2001) Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131: 2197-2203
44. Yu CW, Shin YG, Chow A, Li YM, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, van Breeman RB (2002) Human, rat, and mouse metabolism of resveratrol. Pharm Res 19: 1907-1914
45. Ziegler CC, McEntree MF, Hansen-Petrik M, Johnson BT, Whelan J (2001) In vivo effect of trans-resveratrol on intestinal tumorigenesis. FASEB J 15: A617